BPC-157 + TB-500 + Thymosin Alpha-1 Post-Surgery Recovery Stack

BPC-157 is administered subcutaneously near the surgical site at 250-500 mcg once or twice daily, typically starting 3-7 days post-surgery once initial wound closure is stable. TB-500 is dosed at 2-5 mg subcutaneously once or twice weekly during the loading phase (first 4 weeks), then once weekly for maintenance. Thymosin alpha-1 is administered subcutaneously at 1.6 mg twice weekly for immune support, beginning 1-3 days pre-surgery when possible and continuing for 4-6 weeks post-operatively. The full stack typically runs 6-8 weeks. BPC-157 and TB-500 can be mixed in the same syringe for convenience. Thymosin alpha-1 should be administered at a separate injection site. All protocols should be discussed with the treating surgeon — some may prefer to delay peptide initiation until the initial inflammatory phase (48-72 hours) necessary for proper wound healing has completed.